Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG announced that management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company plans to provide an overview of its late-stage portfolio, highlighting Privosegtor for optic neuropathies and Licaminlimab for dry eye disease. Management noted that Privosegtor targets an estimated potential market opportunity of over $7 billion in the U.S.
Key figures
- Market opportunity usd
- $7B+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.